# Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

> **NCT03430882** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Sapanisertib

## Key facts

- **NCT ID:** NCT03430882
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-12
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430882, "Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03430882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*